T2 RNases, which are evolutionarily conserved tumor suppressors, can slow tumor growth in vivo by bringing in adaptive antitumor CD8+ T lymphocytes and balancing the M1/M2 macrophage ratio in tumors [84,90]. Here, CD8A is linked to neoplasm.